The highly sought-after Apple Watch Series 9 and Watch Ultra 2 face the looming threat of being pulled from US shelves, potentially impacting holiday sales, as a patent dispute with medical tech company Masimo takes center stage. The International Trade Commission (ITC) has ruled in favor of Masimo, claiming that Apple has infringed on the technology integral to the blood oxygen sensors embedded in these popular wearables.
The ITC’s decision raises the specter of a ban on the sale of Apple watches in the United States, with the timeline for potential removal as early as Christmas Day. The ruling underscores the challenges posed by intellectual property disputes in the tech industry and the significant impact on consumer electronics.
Apple, known for its innovation in wearable technology, is actively working on software updates and potential workarounds to address the patent infringement claims. The company aims to avert the ban and maintain the availability of these watches to US consumers.
The patent dispute centers around the blood oxygen sensors, a crucial feature in modern smartwatches for health monitoring. Masimo alleges that Apple’s watches incorporate technology that infringes on their patented advancements in this domain.
As the legal battle unfolds, the uncertainty surrounding the future of the Apple Watch Series 9 and Watch Ultra 2 in the US market has prompted concern among consumers and retailers alike. The potential absence of these popular wearables during the holiday season could have repercussions on both Apple’s revenue and the overall smartwatch market.
Apple remains tight-lipped about the specifics of its strategy to address the patent dispute, but industry experts speculate that the company may negotiate with Masimo or seek legal avenues for an appeal. As the clock ticks down to the possible ban, all eyes are on Apple to navigate this challenge and determine the fate of these cutting-edge wearables in the United States.